National Merit Scholarship, Government of India (1997)

Linnaeus-Palme Scholar, Karolinska Institute (2005)

Shell Centenary Scholar, University of Cambridge (2007-2008)

Commonwealth Scholar, University of Cambridge (2007-2008)

Jawaharlal Nehru Scholar, University of Cambridge (2007-2008)

Hinduja Scholar, University of Cambridge (2007-2008)

Gonville and Caius College Travel grant, International Health Conference, Yale University, April 2005

International Scholar, University of Pittsburgh (2009-2012)

American Society of Clinical Oncology (ASCO) Breast cancer symposium merit award, September 2011

American Association of Cancer Research (AACR) scholar-in-training award, December 2011

Markey Cancer Center Research Boot Camp Director’s award, October 2015

Fellowship of the American College of Physicians (FACP), September 2016

University of Kentucky Edward Romond Teaching award, June 2017




Refereed/invited articles

  1. Soman CR, Mathew A. HIV-1 prevalence in young adults in south India. Lancet. 2006 Jul; 368(9530): 113.

  2. Seidel D, Muangpaisan W, Hiro H, Mathew A, Lyratzopoulos G. The association between body mass index and Barrett’s esophagus: a systematic review. Dis Esophagus. 2009;22(7):564-70

  3. Krishnankutty RK, Mathew A, Sedimbi SK, Suryanarayan S, Sanjeevi CB. Alternative routes of insulin delivery. Journal of central South University Medical Sciences 2009 Oct;34(10):933-48

  4. Muangpaisan WMathews AHori HSeidel D. A systematic review of the worldwide prevalence and incidence of Parkinson’s disease. J Med Assoc Thai. 2011 Jun; 94(6):749-55.

  5. Mathew A, Brufsky A Decreased risk of breast cancer associated with oral bisphosphonate therapy. Breast Cancer: Targets and Therapy Volume 2012:75 – 81

  6. Brufsky AM, Sereika SM, Mathew A, Tomifumi O, Singh V, Rosenzweig M. Long-term treatment with intravenous bisphosphonates in metastatic breast cancer: a retrospective study. Breast J. 2013 Sep-Oct;19(5):504-11.

  7. Mathew A, Brufsky A. The bone substudy of MA.27: does bone make a difference? Lancet Oncol. 2014 Apr;15(4):375-7.

  8. Mathew A, Brufsky A. Bisphosphonates in breast cancer. Int J Cancer.  2015 Aug 15;137(4):753-64.

  9. Mathew A, Brusky A. The use of adjuvant bisphosphonates in the treatment of early-stage breast cancer. Clinical Advances in Hematology & Oncology 2014 Nov;12(11):749-755

  10. Mathew A, Brufsky A. Zoledronic acid – more than just a bone drug. Nature Reviews Clinical Oncology. 2014 Oct;11(10):564-5.

  11. Mathew A, Brufsky A. Bisphosphonates do not reduce breast cancer in postmenopausal women. Annals of Internal Medicine. 2015 Jan 20;162(2):JC5.

  12. Mathew A, Brufsky A. Bisphosphonates in breast cancer: a triple winner? Oncology. 2015 Jan 15;29(1). pii: 203346.

  13. Mathew A, Brufsky AM, Davidson NE. Can circulating tumor cells predict endocrine resistance in metastatic breast cancer? Clinical Cancer Research 2015 Jun 1;21(11):2421-3.2015.

  14. Brufsky A, Mathew A. Bisphosphonates, bone, and breast cancer recurrence. Lancet.2015 Oct 3;386(10001):1319-20.

  15. Mathew A, Davidson NE. Adjuvant endocrine therapy for premenopausal women with hormone-responsive breast cancer. Breast. 2015 Nov;24 Suppl 2:S120-5.

  16. Wang P, Bahreini A, Gyanchandani R, Lucas PC, Hartmaier RJ, Watters RJ, Jonnalagadda AR, Trejo Bittar HE, Berg A, Hamilton RL, Kurland BF, Weiss KR, Mathew A, Leone JP, Davidson NE, Nikiforova MN, Brufsky AM, Ambros TF, Stern AM, Puhalla SL, Lee AV, Oesterreich S. Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients. Clinical Cancer Research. 2016 Mar 1;22(5):1130-7.

  17. Jacob A, Weiss H, Mathew A. The Impact of General Strike on Government Healthcare Delivery in Kerala State in India. J Environ Public Health.2016;2016:8096082.

  18. Jacob A, Unnikrishnan DC, Mathew A, Thyagarajan B, Patel S. A case of fatal Guillain-Barre syndrome from anti-PD1 monoclonal antibody use. J Cancer Res Clin Oncol. 2016 Jun 17

  19. Sandhu GS, Erqou S, Patterson H, Mathew A. Prevalence of Triple-Negative Breast Cancer in India: Systematic Review and Meta-Analysis. Journal of Global Oncology. June 29, 2016, doi:10.1200/JGO.2016.005397

  20. Jacob A, Mathew A. Optimal Use of Bone-Targeted Agents in Breast Cancer. Oncology (Williston Park). 2016 Aug;30(8).pii:218395

  21. Mathew A, Rajagopal M R. Care of the Terminally Ill Patient in India: Comments on the Proposed Legislation. Journal of Global Oncology. Oct 5, 2016.

  22. Henry D, Rudzik F, Butts A, Mathew A. Capecitabine-Induced Coronary Vasospasm. Case Reports in Oncology. 2016, 9 (3), 629-632.

  23. Mathew A, Romond EH. Systemic therapy for HER2-positive early-stage breast cancer. Current Problems in Cancer. 2016 Mar-Aug;40(2-4):106-116. PMID: 27816189

  24. Mathew A, Brufsky A. Less is more? De-intensification of therapy for early-stage HER2-positive breast cancer. Lancet Oncology. 2017 Apr;18(4):428-429. PMID: 28238596

  25. Jacob A, Mathew A. End-of-life care and opioid use in India: Challenges and opportunities. Journal of Global Oncology.2016. 2016.008490.

  26. Mathew IE, Mathew A. Rising thyroid cancer incidence in southern India: an epidemic of overdiagnosis. Journal of Endocrine Society. 2017; 1 (5), 480-487

  27. Mathew A, Rajagopal PS, Villgran V, Sandhu GS, Jankowitz RC, Rosenzweig M, Oesterreich S, Brufsky A. Distinct pattern of metastases in patients with invasive lobular carcinoma of the breast. Geburtshilfe und Frauenheilkunde 2017; 77(6) 660-666

  28. Mathew A, Brufsky A. TACT2: improving treatment tolerability in early breast cancer. Lancet Oncology. 2017 Jul;18(7):843-845. PMID: 28677561

  29. Hilal T, Nakazawa M, Hodskins J, Villano JL, Mathew A, Goel G, Wagner L, Arnold SM, DeSimone P, Anthony LB, Hosein PJ. Comprehensive genomic profiling in routine clinical practice leads to a low rate of benefit from genotype-directed therapy. BMC Cancer. 2017 Aug 30;17(1):602 PMID:28854908

  30. Mathew A, Achkar T, Abberbock S, Sandhu GS, Jacob ME, Villgran VD, Rosenzweig MQ, Puhalla S, Brufsky AM. Prevalence and determinants of end-of-life chemotherapy use in patients with metastatic breast cancer. Breast J. 2017 Aug 28 PMID:28845536

  31. Butterbaugh ST, Patel R, Romond E, Mathew A. Trastuzumab use in patients with durable complete response in HER2 amplified metastatic breast cancer: to continue or not to continue. Annals of Oncology 2017 Dec 1;28(12)3098-3099. PMID: 28950320.

  32. Patel R, Maxwell S, Yan D, Dressler E, Romond E, Mathew A. Medical Oncologists’ Perception of Anti-Estrogen Therapy Benefit in Premenopausal Women with Hormone Receptor-Positive Early Breast Cancer. Annals of Oncology. 2017 Nov 2. PMID: 29106453

  33. R J HartmaierS E TrabuccoN PriedigkeitJ H Chung,  C A ParachoniakP Vanden BorreS MorleyM RosenzweigL M GayM E GoldbergJ SuhS AliJ RossB Leyland-JonesB YoungC WilliamsB ParkM TsaiB HaleyJ PegueroR D CallahanI SachelarieJ ChoJ M AtkinsonA BahreiniA M NagleS L PuhallaR J WattersZ Erdogan-YildirimL CaoS OesterreichA MathewP C LucasN E DavidsonA M BrufskyG M FramptonP J StephensJ ChmieleckiA V Lee. Recurrent hyperactive ESR1 fusion proteins in endocrine therapy resistant breast cancer. Annals of Oncology 29: 872–880, 2018 doi:10.1093/annonc/mdy025

  34. Mathew A. Global Survey of Clinical Oncology Workforce. Journal of Global Oncology. Feb 2018. DOI: 10.1200/JGO.17.00188

  35. Varešlija D, Priedigkeit N, Fagan A, Purcell S, Cosgrove N, O’Halloran PJ, Ward E, Cocchiglia S, Hartmaier R, Castro CA, Zhu L, Tseng GC, Lucas PC, Puhalla SL, Brufsky AM, Hamilton RL, Mathew A, Leone JP, Basudan A, Hudson L, Dwyer R, Das S, O’Connor DP, Buckley PG, Farrell M, Hill ADK, Oesterreich S, Lee AV, Young LS. Transcriptome Characterization of Matched Primary Breast and Brain Metastatic Tumors to Detect Novel Actionable Targets. J Natl Cancer Inst. 2018 Jun 28. doi: 10.1093/jnci/djy110. 29961873

  36. Mathew A. Global research partnerships in advancing public health: A case study on India. Indian J Med Ethics. 2018 June 2nd.

  37. Sekkath Veedu J, Mathew A. Are we missing the elephant in the room – A case for thyroid cancer overdiagnosis as the etiology for its rising incidence in India? Journal of Global Oncology. 2018. doi:10.1200/JGO.18.00177.

  38. Mathew A, Erqou S. Can estrogen receptor status predict for shorter duration of adjuvant trastuzumab in early-stage breast cancer? Annals of Oncology. 2018 Oct 24. Doi:10.1093/annonc/mdy478.

Mathew A. Cancer burden in India. Lancet Oncology 2018.

Book chapters

  1. Mathew A, Bahary N. Systemic therapy in pancreatic cancer. Multidisciplinary Management of Gastrointestinal Cancers. World Scientific. 2016.

  2. Mathew A, Wallis NK, Brufsky A. Metastatic breast cancer. Essential Oncology. February 2017.

Mathew A, Brufsky A. Adjuvant Bisphosphonates in Breast Cancer. The Breast. Comprehensive management of benign and malignant disease. 5th Edition. 1st September 2017.

Published abstracts

  1. Shastry A, Rajalingam R, Mathew A, Krishnankutty RK, Sedimbi SKK, Rumba I,    Sanjeevi CB. Activating KIR genes of innate immunity is associated with protection in Latvian patients with Autoimmune Diabetes in Adults. Tissue Antigens. 2006 Jun; 67(6): 535.

  2. Soman CR, Joseph A, Mathew A, Ajayan K. Emerging epidemic of Type 2 Diabetes in rural Kerala, India. Diabet Med. 2006 Dec;23 Suppl 4:1-788.

  3. Soman CR, Mathew A, Ajayan K, Joseph A. Increased risk of type 2 Diabetes in relation to waist circumference in Kerala, India. Diabet Med. 2006 Dec;23 Suppl 4:1-788.

  4. Soman CR, Mathew A, Joseph A, Ajayan K. Relationship between waist circumference, fasting plasma glucose levels and serum lipid levels in non-diabetic normoglycemic subjects. Diabet Med. 2006 Dec;23 Suppl 4:1-788.

  5. Mathew A, Rosenzweig M, Brufsky AM Association of bisphosphonate use with overall survival in metastatic breast cancer J Clin Oncol 29, 2011 (suppl 27; abstr 102)

  6. Mathew A, Rosenzweig M, Brufsky AM Prognostic role of triple negative status in breast cancer with brain metastases. J Clin Oncol 29, 2011 (suppl 27; abstr 36)

  7. Mathew A, Mathew IE, Rosenzweig M, Brufsky AM Association of bisphosphonate use with overall survival in metastatic breast cancer. Cancer Res 2011;71(24 Suppl);477s.

  8. Mathew A, Mathew IE, Rosenzweig M, Brufsky AM Prognostic role of triple negative status in breast cancer with brain metastases. Cancer Res 2011;71(24 Suppl):Abstract nr P4-17-06.

  9. Mathew A, Brufsky AM (2013, December). Risk of CNS relapse following adjuvant trastuzumab therapy – updated literature-based meta-analysis. Cancer Research 2013;73(24 Suppl);December 15, 2013: Abstract nr P6-11-08.

  10. Mathew A, Woytowitz D, Smith RE, Mehta RP (2013, December). Tacrolimus-induced refractory immune thrombocytopenia in solid organ transplant patients. November 15, 2013; Blood: 122 (21)

  11. Villgran V, Aju Mathew, et al. Effect of tumor subtype on overall survival in brain metastatic breast cancer patients treated with cranial irradiation. J Clin Oncol 32, 2014 (suppl 26; abstr 74) – co-first author

  12. Hartmaier RJ, Puhalla SL, Oesterreich S, Bahreini A, Mathew A, Davidson NE, Brufsky AM, Lee AV. Identification of base pair mutations and structural rearrangements acquired in breast cancer metastases including a novel hyperactive ESR1-DAB2 fusion gene specifically in hormone-resistant recurrence. Cancer Res December 10, 2013 74:S1-03.

  13. Puhalla S, Wang P, Bahreini A,  Gyanchandani R, Ambros T, Hartmaier R, Kurland BF, Lucas P, Bittar HT, Hamilton R, Mathew A, Leone J, Davidson NE, Weiss KR, Waters RJ, Nikiforova M, Stern A, Brufsky A, Lee AV, Oesterreich S. Detection and functional analysis of estrogen receptor mutations (ESR1-mut) in patients with metastatic breast cancer. J Clin Oncol 33, 2015 (suppl; abstr 554)

  14. Rajagopal PS, Jacob M, Villgran V, Rosenzweig M, Jankowitz R, Oesterreich S, Brufsky A, Mathew A. Metastatic pattern of invasive lobular carcinoma. J Clin Oncol 33, 2015 (suppl; abstr e11561)

  15. Pandey A, Jacob M, Mazur L, Brufsky A, Mathew A. Is Body Mass Index a prognostic factor in early-stage breast cancer patients who subsequently developed metastatic disease? J Clin Oncol 33, 2015 (suppl; abstr e12639)

  16. Achkar T, Jacob M, Villgran V, Abberbock S, Rosenzweig M, Puhalla S, Brufsky A, Mathew A. End-of-life chemotherapy use in metastatic breast cancer. J Clin Oncol 33, 2015 (suppl; abstr e20505)

  17. Riccelli V*, Zhang JJ*, Bhargava R, Lu H, Mathew A, Donnenberg AD, Donnenberg VS. Tumor-Associated Macrophages (TAMs) are Associated with Epithelial-to-Mesenchymal Transition in Primary Breast Cancer.  Cyto 2015. June 24-27, Glasgow, Scotland, UK.

  18. Sandhu GS, Erqou S, Patterson H, Mathew A. Prevalence of triple negative breast cancer in India – systematic review and meta-analysis. J Clin Oncol 34, 2016 (suppl; abstr e12561)

  19. Hilal T, Nakazawa M, Hodskins J, Arnold S, DeSimone P, Wagner L, Anthony L, Chambers MD, Villano JL, Mathew A, Goel G, Romond E,Thind R, Wang P, Hosein PJ. Utility of comprehensive genomic profiling (CGP) at an NCI-designated cancer center for identifying clinically relevant genomic alterations (CRGA) and implementing genomically directed therapy (GDT). J Clin Oncol 34, 2016 (suppl; abstr e18018)

  20. Hartmaier, Priedigkeit N, Gay L, Goldberg ME, Sug J, Ali S, Ross J, Tsai M, Haley B, Peguero J, Callahan RD, Sachelarie I, Cho J, Bahreini A, Puhalla, S, Oesterreich S, Mathew A, Lucas P, Davidson NE, Brufsky A, Stephens PJ, Chmielecki J, Lee AV. Comprehensive genomic analysis of metastatic breast cancers reveals ESR1 fusions as a recurrent mechanism of endocrine resistance. Cancer Research. 77 (13) 421.

  21. Wesolowski R, Lustberg MB, Reinbolt RE, VanDeusen JB, Sardesai SD, Williams NO, Noonan AM, Deani SJ, Poi M, Wilson D, Grever M, Stephens J, Puhalla S, Mathew A, Carson WE, Ramaswamy B. Phase Ib study of heat shock protein 90 inhibitor, onalespib in combination with paclitaxel in patients with advanced, triple-negative breast cancer (NCT02474173). Journal of Clinical Oncology 2017. 35 (15_supplement) TPS1127

  22. Panjikaran LD, Mathew A. Using Effective Web-based Tools to Address Cancer Healthcare Disparities. J Clin Oncol 36, 2018 (suppl 7S; abstr 76)

  23. Butterbaugh S, Roy AM, Hasanein H, Patel RA, Mathew A. Prospective registration of cancer clinical trials in India. Journal of Clinical Oncology 2018 36:15_suppl, e18863

  24. Arays R, Tran-Harding K, Wu J, Yan D, Durbin EB, Marcinkowski EF, McGrath P, Hawthorne K, Romond EH, Chambers MD, Gibbs R, Mathew A. Neglected breast cancer in the Appalachians. Journal of Clinical Oncology 2018 36:15_suppl, e13023

Veedu JS, Wang K, Lei F, Chen Q, Huang B, Mathew A. Trends in thyroid cancer incidence in India. J Clin Oncol 36, 2018 (suppl; abstr e18095)


  1. Mathew A, Rajalingam R, Krishnankutty RK, Shastry A, Sedimbi SK, Rumba I, Sanjeevi CB. (2006, April). MHC molecules and KIR genes in autoimmune diabetes in adults. Poster presented at: Indo-Swedish Symposium on Genomics and Proteomics of Diabetes; Chennai, India.

  2. Mathew IE, Mathew A, Zielinski D. (2011, March). A confusing case of blindness: Giant cell arteritis. Poster presented at: Society of General Internal Medicine Mid-Atlantic conference; Baltimore, MD.

  3. Mathew IE, Rao N, Mathew A. (2011, March). An unusual ‘infectious’ case of rhabdomyolysis: Legionnaire’s disease. Poster presented at: Society of General Internal Medicine Mid-Atlantic conference; Baltimore, MD.

  4. Mathew A, Mathew IE, Rosenzweig M, Brufsky AM (2011, June). Association of Bisphosphonate use with overall survival in metastatic breast cancer. Poster presented at the University of Pittsburgh Cancer Institute Scientific retreat; June 2011; Pittsburgh USA

  5. Villgran V, Mathew A, Rosenzweig MQ, Abberbock S, Naik RD, Jacob M, Brufsky A. (March 2015) Prevalence of tumor subtypes among long-term survivors of brain metastatic breast cancer. Poster presentation at; NCCN 20th Annual Conference. Hollywood, Florida.

  6. Bodine C, Mathew A. (September 2016) Case of HER2-positive invasive lobular carcinoma. First Invasive Lobular Carcinoma Symposium. Pittsburgh, Pennsylvania.

  7. Henry D, Rudzik F, Butts A, Mathew A. (October 2016) Capecitabine induced coronary vasospasm. American Medical Association meeting. Orlando, Florida.

  8. Patel D, Maxwell S, Yan D, Dressler E, Mathew A. (May 2017) Oncologists’ perception of anti-estrogen therapy benefit. Markey Cancer Center Research Day.

  9. Arrays R, Mathew A. (May 2018) Neglected breast cancer in Appalachians. 6th Markey Breast Cancer Symposium.

Veedu J, Mathew A. (May 2018) Thyroid Cancer Trends in India. Markey Research Day.

Speaking Activities

  1. Vaccines in Type 1 Diabetes. Oral Presentation at: Seminar, Department of Molecular Medicine, Karolinska Institute; Stockholm, Sweden (2005, September).

  2. Smoking and cardiovascular disease: Individual participant meta-analysis involving 201,714 persons in 20 prospective studies of the Emerging Risk Factors Collaboration. Oral Presentation at: Cardiovascular disease Forum; Cambridge, United Kingdom (2008, August).

  3. Spotlight on clinical cases: Hypercoagulability and Ewing sarcoma. Oral presentation at Medical Grand Rounds; Department of medicine, University of Pittsburgh Medical Center, USA (2010, May).

  4. Management of bone complications in cancer. Oral presentation at the Department of Internal Medicine senior talk, University of Pittsburgh Medical Center, Pittsburgh USA (2012, February).

  5. Advances in HER2 targeted therapy in metastatic breast cancer. Oral presentation at the General tumor board, University of Pittsburgh Cancer Institute, Pittsburgh, USA (2013, June).

  6. Light chain deposition disease & Systemic AL amyloidosis. Specialist discussant, Veterans Affairs Chief of medicine conference, Pittsburgh, USA (2013, October).

  7. Q & A sessions for participants of LIFE study. Pittsburgh, USA (August 2014).

  8. Bisphosphonates in Breast Cancer. Medical Grand Rounds. University of Kentucky Department of Internal Medicine (2015, September).

  9. Pre-clinical trial in Triple Negative Breast Cancer. Markey Clinical Trials Boot Camp. Kentucky (2015, October).

  10. Early-Stage Breast Cancer Management. Medical Grand Rounds. Clark Regional Hospital, Kentucky (2015, October).

  11. Breast cancer 101 – Grand Rounds, Georgetown hospital, Kentucky (2016, September)

  12. Adjuvant endocrine therapy in young women with breast cancer. Invited lecture at Manipal Breast cancer symposium, Manipal, India (2017, February).

  13. Triple Negative Breast Cancer. Invited lecture at the Breast Cancer Symposium, IISER Pune, India (2017, February).

  14. Breast Cancer – Challenges and Opportunities. Invited lecture at Frankfort Regional Medical Center CME program. Frankfurt, Kentucky, USA (2017, September).

  15. Adjuvant therapy in premenopausal women with breast cancer – Grand Rounds, UK Department of Pathology, Kentucky (2018, March).

  16. Management of adverse effects of immunotherapy. 2nd Markey Precision Medicine Symposium. Lexington, Kentucky, USA (2018, April).

  17. The great breast cancer screening conundrum – Grand Rounds, UK Department of Medicine, Kentucky (2018, April).

  18. Cancer disparities and impact of outcomes. Summit on Cancer Health Disparities. Seattle, Washington, USA (2018, April).

  19. Application of genomics in breast cancer clinic. Medgenome Cancer Genomics Symposium. Foster City, California, USA (2018, May).

  20. HER2 positive breast cancer – what’s new? 6th Markey Breast Cancer Symposium. Lexington, KY, USA (2018, May).

  21. Adjuvant endocrine therapy in breast cancer – changing paradigm. Oncology 2018. Kochi, India (2018, Sept).

  22. Emerging opportunities with PARP inhibitor therapy in cancer. Oncology 2018. Kochi, India (2018, Sept).

  23. Primitive Neuroectodermal Tumor. Oncology 2018. Kochi, India. (2018, Sept).

Update on novel endocrine therapy in metastatic breast cancer. Wilmington VA hospital, Delaware, USA (2018, Oct).